Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
about
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABAHealth-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literatureAirway and Extracellular Matrix Mechanics in COPDA rational approach to single, dual and triple therapy in COPDTiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaComparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisLong-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysisClinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseProfile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDChronic obstructive pulmonary disease: respiratory review of 2013Combination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseaseCan roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalInhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)COPD: maximization of bronchodilation.Chronic obstructive pulmonary disease: respiratory review of 2014.Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE studyIndacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysisIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practiceThe lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Indacaterol: a comprehensive review.Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis.Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
P2860
Q26752988-7576FA55-6A03-488B-8ADB-9CB47C93D067Q26765780-8D6762DD-4C35-4268-BBCA-7F8E86B16F2CQ26773109-031DC49D-08A9-4D6B-A7AE-34DCD3134174Q26776477-A5F4512F-B511-49DA-8AF4-78A81B430A6CQ26780553-5F843AD2-CBC5-4814-A5A7-02953A1A3E4CQ26782484-0C9A88D9-4A17-4B31-8FDC-B8DA7A69B11EQ26800134-2BB090F5-4692-4093-A316-298EEF93FD84Q26801134-7EC86EDB-DCA0-4B69-8F6E-6E9C4303CCEEQ26801661-B7F62244-4A20-4F26-9867-AC75FA8E9BF5Q26825822-19FA7EE3-3896-47EB-9103-1D13168AA5D3Q26864703-416AE3C5-D59D-4972-961A-C11D05B39726Q27012625-5D26F084-E4C0-444D-8303-43DB3CCE17B7Q27024384-975BF190-1C23-4438-AFB1-C6FBEB1BE9FFQ27348844-EAA74014-F3DD-4599-9F89-85EEE133322EQ28068078-82699A2C-B754-485C-8528-4DB9D4A430BCQ28070108-2F84D896-22C8-4681-8C55-353FFCC27AD9Q28074169-35DB3CBB-2DBB-4DE0-8322-8255CDE3C851Q28087788-F6DC49EA-6C35-498E-9EE6-F84DDE89E324Q30238494-B0825BA5-39B1-4A95-95A8-5B0D0F0C5FDAQ33649840-E86A1263-D4AA-403F-9ACB-C7D88C533F69Q33854276-9B1A8764-08C7-4026-B7EB-014F98F015F6Q34003435-559B9123-3AB9-4D5E-B85A-71085E6C943BQ34436393-4141F907-93E0-4BB6-90BD-89205204080AQ34440060-265049F0-2F09-453D-92B2-B4477C6E48E8Q34944637-6D958FC7-73D5-4BA1-BD45-0474A1D1D1B7Q34962838-159C4E91-2793-44E4-B39D-7BF2EE2A194DQ35140742-8217DA6C-9D27-46A2-B350-8A1CFC3A992AQ35350962-06C345A5-E225-4162-BC44-76B3E8411B90Q35541687-6472C3B4-3A1C-48E2-BF72-F0FB444D6289Q35703517-842E7D81-99B7-4069-B4B1-3422877B1AB4Q35749377-1DA2D877-70B3-4DAB-85BB-A5EDE9DBE53EQ36208427-D0BEF4B5-27DC-4F40-81C4-1E1D53079CA9Q36302882-1412A04B-A79E-45FA-9CCA-E29B4CF459E7Q36329064-E7B7C33F-5E60-4183-BA52-F74AE6272C87Q36332206-EE4C38CB-35B9-4871-AD06-CB04DBE56A8FQ36557670-049884D0-BDB4-422A-9008-AC7AE1FEEAFEQ36907742-177B8D43-478A-4311-AA19-2A457DCA0E68Q37057061-6719C04D-221E-4288-BF4E-6F7E7B0AE1B1Q37109222-5C1A482E-FDD3-4851-BEFA-2E4412DFE84AQ37247499-E6883FA2-9789-4EA8-8509-470ADABD2264
P2860
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Efficacy and safety of once-da ...... e-blind, parallel group study.
@en
Efficacy and safety of once-da ...... e-blind, parallel group study.
@nl
type
label
Efficacy and safety of once-da ...... e-blind, parallel group study.
@en
Efficacy and safety of once-da ...... e-blind, parallel group study.
@nl
prefLabel
Efficacy and safety of once-da ...... e-blind, parallel group study.
@en
Efficacy and safety of once-da ...... e-blind, parallel group study.
@nl
P2093
P1476
Efficacy and safety of once-da ...... e-blind, parallel group study.
@en
P2093
Claus F Vogelmeier
Donald Banerji
Eric D Bateman
Hungta Chen
John Pallante
Peter D'Andrea
Vijay K T Alagappan
P356
10.1016/S2213-2600(12)70052-8
P577
2012-12-06T00:00:00Z